RIGI and breast cancer: It was also recently reported that SLR20, an SLR family member that is 20 bp in length, directly targets 4T1 breast cancer cells, which are another poorly immunogenic class of tumors, to activate the RIG-I signaling pathway (Elion et al., 2018).